La Jolla Pharmaceutical Co Submits SEC Filing

Strategic Insights -

A recent SEC filing by La Jolla Pharmaceutical Co has highlighted the company's biopharmaceutical activities. The document, filed on June 17, 2022, reveals the company's focus on biological products and diagnostic substances. According to the filing, the company is committed to transparency and compliance with SEC regulations, as evident from the detailed information provided in the document. This filing is a significant development for investors and analysts tracking La Jolla Pharmaceutical Co's progress in the biotech sector.

Key Takeaways:

  • La Jolla Pharmaceutical Co has submitted an SEC filing (Form 4) on June 17, 2022, which provides information on the company's ownership and equity securities.
  • The filing reveals that the company operates in the biopharmaceutical sector, with a focus on biological products and diagnostic substances.
  • The SEC filing is a requirement for publicly-traded companies to disclose information on executive officers, directors, and significant shareholders.
  • The company's SIC code is 2836, indicating its classification as a biological product manufacturer.
  • The filing includes contact information for La Jolla Pharmaceutical Co, with the company's address and phone number provided.

Statistics:

  • The filing was submitted on Form 4, which is used for reporting changes in ownership and executive compensation.
  • The SEC filing was made on June 17, 2022, with a filing date of June 17, 2022.
  • The company's SIC code is 2836, which corresponds to the biological product manufacturing industry.
  • The contact information for the company includes an address at 201 JONES ROAD, SUITE 400, WALTHAM MA 02451 and a phone number of 617-715-3600.

Sources:

  • NewsRx
  • U.S. Securities and Exchange Commission (SEC)
  • La Jolla Pharmaceutical Co Registration Statement (Form 4)

https://www.sec.gov/Archives/edgar/data/1759910/0001209191-22-037956-index.html